射血分数保留的心力衰竭研究进展

Advances in the study of heart failure with preserved ejection fraction

射血分数保留的心力衰竭(HFpEF)是一种在病理生理学和临床表现等方面异质性较高的综合征,随着人口老龄化,高血压、心房颤动、糖尿病、慢性肺部疾病等疾病的增多,HFpEF的患病率也在持续升高。但由于其机制表现的复杂性和异质性,传统的心力衰竭治疗药物对HFpEF相关的研究并未显示出有明显的益处,临床研究屡屡受挫,治疗上仍少有突破进展,当前越来越强调针对发病机制来进行精准治疗,其病理生理学、诊断标准和临床治疗仍存在争议,现作一综述。

Heart failure with preserved ejection fraction(HFpEF)is a syndrome that is highly heterogeneous in terms of pathophysiology and clinical manifestations,and the prevalence of HFpEF is increasing with the ageing of the population and the increase in hypertension,atrial fibrillation,diabetes and chronic lung diseases.However,due to the complexity and heterogeneity of the mechanism of presentation,traditional heart failure treatment drugs have not shown significant benefit in studies related to HFpEF,and clinical studies have been repeatedly frustrated,with few breakthroughs in the treatment.There is an increasing emphasis on precision therapy targeting the pathogenesis,and the pathophysiology,diagnostic criteria and clinical treatment are still controversial,and are reviewed here.